Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein

Gene Therapy

Volumn 10, Issue 25, 2003, Pages 2090-2097

  Lehtolainen, P ^a   Wirth, T ^a   Taskinen, A K ^a   Lehenkari, P ^b   Leppanen O ^a   Lappalainen, M ^a   Pulkkanen, K ^a   Marttila, A ^c   Marjomaki V ^c   Airenne, K J ^a   Horton, M ^b   Kulomaa, M S ^c   Yla Herttuala S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Department of Medicine   (United Kingdom)

^c UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

Avidin; Avidin mutations; Biotin; Low density lipoprotein receptor; Targeting

Indexed keywords

AVIDIN; BIOTIN; CYTOTOXIC AGENT; DRUG CARRIER; HYBRID PROTEIN; LIGAND; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; BIOTINYLATION; CELL MEMBRANE; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENE TRANSFER; GLIOBLASTOMA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; RAT; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; AVIDIN; BIOTIN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL FRACTIONATION; CELL MEMBRANE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; GLIOMA; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, FLUORESCENCE; RATS; RECEPTORS, LDL; RECOMBINANT FUSION PROTEINS; SEMLIKI FOREST VIRUS;

ANIMALIA;

EID: 10744221223     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302120     Document Type: Article

References (38)

1. Wilchek M, Bayer EA. Introduction to avidin-biotin technology. Methods Enzymol 1990; 184: 5-13.
2. Breitz HB et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J Nucl Med 2000; 41:131-140.
3. Penichet ML et al. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J Immunol 1999; 163: 4421-4426.
4. Axworthy DB, Reno JM, Hylarides MD et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97: 1802-1807.
5. Green RM. Avidin. Adv Protein Chem 1975; 29: 85-133.
6. Subbiah K et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med 2003; 44: 437-445.
7. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003; 44: 400-411.
8. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987; 28: 1294-1302.
9. Pardridge WM, Boado RJ, Buciak JL. Drug delivery of antisense oligonucleotides or peptides to tissues in vivo using an avidin-biotin system. Drug Delivery 1993; 1: 43-50.
10. Shin SU et al. Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol 1997; 158: 4797-4804.
11. Shi N, Boado RJ, Pardridge WM. Antisense imaging of gene expression in the brain in vivo. Proc Natl Acad Sci USA 2000; 97: 14709-14714.
12. Kassis AI, Jones PL, Matalka KZ, Adelstein SJ. Antibody-dependent signal amplification in tumor xenografts after pretreatment with biotinylated monoclonal antibody and avidin or streptavidin. J Nucl Med 1996; 37: 343-352.
13. Klibanov AL et al. Blood clearance of radiolabeled antibody: enhancement by lactosamination and treatment with biotin-avidin or anti-mouse IgG antibodies. J Nucl Med 1988; 29: 1951-1956.
14. Yamamoto T et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
15. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001; 248: 91-101.
16. Banerjee SK et al. Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis. Carcinogenesis 1997; 18: 1155-1161.
17. Sato Y et al. In vivo gene delivery to tumor cells by transferring-streptavidin-DNA conjugate. FASEB J 2000; 14: 2108-2118.
18. Paganelli G et al. In vivo labelling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization. Int J Cancer Suppl 1988; 2: 121-125.
19. Di CV et al. Preoperative and intraoperative radioimmuno-detection of cancer pretargeted by biotinylated monoclonal antibodies. Semin Surg Oncol 1998; 15: 235-238.
20. Paganelli G et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999; 26: 348-357.
21. Corti A et al. Tumor targeting with biotinylated tumor necrosis factor alpha: structure-activity relationships and mechanism of action on avidin pretargeted tumor cells. Cancer Res 1998; 58: 3866-3872.
22. Guttinger M et al. Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 2000; 60: 4211-4215.
23. Xu X et al. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000; 60: 4475-4484.
24. Grana C et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study Br J Cancer 2002; 86: 207-212.
25. Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin. Nucl Med Commun 1991; 12: 211-234.
26. Marttila AT et al. Recombinant neutralite avidin: a nonglycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non-specific binding properties. FEBS Lett 2000; 467: 31-36.
27. Laitinen OH et al. Biotin induces tetramerization of a recombinant monomeric avidin. A model for protein-protein interactions. J Biol Chem 2001; 276: 8219-8224.
28. Lehtolainen P et al. Cloning and characterization of scavidin, a fusion protein for the targeted delivery of biotinylated molecules. J Biol Chem 2002; 277: 8545-8550.
29. Penman M et al. The type I and type II bovine scavenger receptors expressed in Chinese hamster ovary cells are trimeric proteins with collagenous triple helical domains comprising noncovalently associated monomers and Cys83-disulfide-linked dimers. J Biol Chem 1991; 266: 23985-23993.
30. Olkkonen VM et al. Expression of exogenous proteins in mammalian cells with the Semliki Forest virus vector. Methods Cell Biol 1994; 43: 43-53.
31. Bayer EA, Ehrlich RS, Wilchek M. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic method for assessing the quaternary state and comparative thermostability of avidin and streptavidin. Electrophoresis 1996; 17: 1319-1324.
32. Punnonen EL, Marjomäki VS, Reunanen H. 3-Methyladenine inhibits transport from late endosomes to lysosomes in cultured rat and mouse fibroblasts. Eur J Cell Biol 1994; 65: 14-25.
33. Griffiths G, Matteoni R, Back R, Hoflack B. Characterization of the cation-independent mannose 6-phosphate receptor-enriched prelysosomal compartment in NRK cells. J Cell Sci 1990; 95: 441-461.
34. Lehenkari PP, Charras GT, Nykanen A, Horton MA. Adapting atomic force microscopy for cell biology Ultramicroscopy 2000; 82:289-295.
35. Hotter JL, Bechhoefer J. Calibration of atomic-force microscope tips. Rev Sci Instrum 1994; 64: 1868-1873.
36. Lehenkari PP, Horton MA. Single integrin molecule adhesion forces in intact cells measured by atomic force microscopy. Biochem Biophys Res Commun 1999; 259: 645-650.
37. Marjomaki VS et al. Lysosomal trafficking in rat cardiac myocytes. J Histochem Cytochem 1990; 38: 1155-1164.
38. Sandmair AM et al. Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther 2000; 7: 413-421.